Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Equity Average (2019 - 2025)

C4 Therapeutics' Equity Average history spans 7 years, with the latest figure at $205.5 million for Q4 2025.

  • For Q4 2025, Equity Average fell 10.39% year-over-year to $205.5 million; the TTM value through Dec 2025 reached $205.5 million, down 10.39%, while the annual FY2025 figure was $236.3 million, 2.27% up from the prior year.
  • Equity Average reached $205.5 million in Q4 2025 per CCCC's latest filing, up from $164.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $407.6 million in Q3 2021 to a low of $164.2 million in Q3 2025.
  • Average Equity Average over 5 years is $275.0 million, with a median of $252.4 million recorded in 2024.
  • Peak YoY movement for Equity Average: soared 531.38% in 2021, then crashed 32.93% in 2025.
  • A 5-year view of Equity Average shows it stood at $394.2 million in 2021, then decreased by 22.95% to $303.7 million in 2022, then fell by 23.92% to $231.1 million in 2023, then dropped by 0.76% to $229.3 million in 2024, then fell by 10.39% to $205.5 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Equity Average are $205.5 million (Q4 2025), $164.2 million (Q3 2025), and $184.6 million (Q2 2025).